Results 151 to 160 of about 627,562 (273)

Severe Cutaneous Adverse Reactions Associated With Newer‐Generation Antiseizure Medications: A Real‐World Pharmacovigilance Study Based on FAERS and JADER

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
A cross‐database analysis of FAERS and JADER confirmed lamotrigine and zonisamide as the dominant SJS/TEN/DRESS risk drivers across both systems. After polytherapy adjustment, eslicarbazepine (DRESS, ROR 10.41) and levetiracetam emerged as reproducible novel signals warranting clinical attention. SJS/TEN onset concentrated within 4 weeks, whereas DRESS
Longfei You   +4 more
wiley   +1 more source

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC

open access: yesHealth Care Science, Volume 5, Issue 3, Page 196-206, June 2026.
Findings indicate that within a standardized clinical pathway integrating structured immunosuppression, therapeutic drug monitoring, and early complication surveillance, liver transplantation after ICI exposure can be performed safely without increased rejection risk.
Ning Wang   +14 more
wiley   +1 more source

Human Herpesvirus 8

open access: yes
Human herpesvirus (HHV) 8 or Kaposi’s sarcoma associated herpesvirus (KSHV) is the newest member of the HHV family, discovered almost a decade ago in Kaposi’s sarcoma (KS) tissue (1–3).
Mitchell, Charles D, Wood, Charles
core   +1 more source

Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting

open access: yesHemaSphere, Volume 10, Issue 6, June 2026.
Abstract In HIV‐ and tuberculosis (TB)‐endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform—a plasma cell‐free DNA (cfDNA)‐based approach ...
Katherine Antel   +21 more
wiley   +1 more source

Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review

open access: yesHealth Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy.
Sanila Mughal   +7 more
wiley   +1 more source

Human herpesvirus 7 epithelial keratitis with geographic-dendritic ulceration. [PDF]

open access: yesBMC Infect Dis
Ying L   +5 more
europepmc   +1 more source

Primary Cancer Prevention Through Vaccination: Advances, Challenges, and Global Perspectives

open access: yesHealth Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Oncogenic viral and bacterial infections constitute a significant portion of the global cancer burden, accounting for up to 15% of cases, particularly in low‐ and middle‐income countries. Prophylactic vaccination thus appears to be the most effective tool for preventing these preventable cancers, especially those linked to human papillomavirus
Christian Tague   +5 more
wiley   +1 more source

Epidemiological Trends and Clinical Characteristics of Epstein–Barr Virus Infection in Febrile Children in Zhejiang, China: A Retrospective Study

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 6, June 2026.
ABSTRACT Background This study aimed to investigate the epidemiological trends, age‐ and sex‐related patterns, and clinical and immunological characteristics of Epstein–Barr virus (EBV) infection among febrile children. Methods We analyzed EBV DNA data from 9151 febrile children and serological antibody profiles from 6934 cases.
Hao Zhou   +4 more
wiley   +1 more source

Human herpesvirus 7 integrates into host telomeres via its telomeric repeat arrays. [PDF]

open access: yesPLoS Pathog
Cheng Y   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy